Niklas Gremke1, Sebastian Griewing2, Saket Chaudhari3, Swati Upadhyaya3, Ivan Nikolov4, Karel Kostev5, Matthias Kalder2. 1. Department of Gynecology and Obstetrics, University Hospital Marburg, Philipps-University Marburg, Baldingerstraße, 35043, Marburg, Germany. Gremken@staff.uni-marburg.de. 2. Department of Gynecology and Obstetrics, University Hospital Marburg, Philipps-University Marburg, Baldingerstraße, 35043, Marburg, Germany. 3. IQVIA, Bangalore, India. 4. Department of Gynecology, Herz Jesu Clinic, Fulda, Germany. 5. Epidemiology, IQVIA, Frankfurt, Germany.
Abstract
PURPOSE: The aim of this study was to analyze the persistence of women on tamoxifen (TAM) and aromatase inhibitors (AIs) in Germany, and to investigate possible determinants of non-persistence. METHODS: The present retrospective cohort study was based on the IQVIA longitudinal prescription database (LRx). The study included women with an initial prescription of TAM or AIs (anastrozole, letrozole, and exemestane) between January 2016 and December 2020 (index date). Kaplan-Meier analyses were performed to show the persistence for TAM and AI, using a therapy gap of 90 or 180 days, respectively. A multivariable Cox proportional hazards regression model was further used to estimate the relationship between non-persistence and drug prescription (AI versus TAM), age, and the specialty of the physician initiating therapy (gynecologist, oncologist, or general practitioner). RESULTS: Up to 5 years after the index date, only 35.1% of AI and 32.5% of TAM patients were continuing therapy when therapy discontinuation was defined as at least 90 days without therapy. Using a 180-day therapy gap, 51.9% of AI and 50.4% of TAM patients remained on therapy after 5 years. Cox regression models reveal that initial therapy with TAM (HR 1.06, 95% CI 1.04-1.07), therapy initiation by oncologists (HR 1.09, 95% CI 1.07-1.11), or general practitioners (HR 1.24, 95% CI 1.21-1.27) and age ≤ 50 (HR 1.08, 95% CI 1.06-1.10) were significantly associated with an increased risk of therapy discontinuation. CONCLUSION: Overall, the present study indicates that persistence rates are low in all age groups for both TAM and AI treatment. We found several factors (e.g., physician specialty, younger age, and type of endocrine therapy) to be associated with an increased risk for non-persistence.
PURPOSE: The aim of this study was to analyze the persistence of women on tamoxifen (TAM) and aromatase inhibitors (AIs) in Germany, and to investigate possible determinants of non-persistence. METHODS: The present retrospective cohort study was based on the IQVIA longitudinal prescription database (LRx). The study included women with an initial prescription of TAM or AIs (anastrozole, letrozole, and exemestane) between January 2016 and December 2020 (index date). Kaplan-Meier analyses were performed to show the persistence for TAM and AI, using a therapy gap of 90 or 180 days, respectively. A multivariable Cox proportional hazards regression model was further used to estimate the relationship between non-persistence and drug prescription (AI versus TAM), age, and the specialty of the physician initiating therapy (gynecologist, oncologist, or general practitioner). RESULTS: Up to 5 years after the index date, only 35.1% of AI and 32.5% of TAM patients were continuing therapy when therapy discontinuation was defined as at least 90 days without therapy. Using a 180-day therapy gap, 51.9% of AI and 50.4% of TAM patients remained on therapy after 5 years. Cox regression models reveal that initial therapy with TAM (HR 1.06, 95% CI 1.04-1.07), therapy initiation by oncologists (HR 1.09, 95% CI 1.07-1.11), or general practitioners (HR 1.24, 95% CI 1.21-1.27) and age ≤ 50 (HR 1.08, 95% CI 1.06-1.10) were significantly associated with an increased risk of therapy discontinuation. CONCLUSION: Overall, the present study indicates that persistence rates are low in all age groups for both TAM and AI treatment. We found several factors (e.g., physician specialty, younger age, and type of endocrine therapy) to be associated with an increased risk for non-persistence.
Authors: Maria Alice Franzoi; Elisa Agostinetto; Marta Perachino; Lucia Del Mastro; Evandro de Azambuja; Ines Vaz-Luis; Ann H Partridge; Matteo Lambertini Journal: Lancet Oncol Date: 2021-04-20 Impact factor: 41.316
Authors: Phillip S Blanchette; Melody Lam; Lucie Richard; Britney Allen; Salimah Z Shariff; Ted Vandenberg; Kathleen I Pritchard; Kelvin K W Chan; Alexander V Louie; Danielle Desautels; Jacques Raphael; Craig C Earle Journal: Breast Cancer Res Treat Date: 2019-10-01 Impact factor: 4.872
Authors: Joyce A Cramer; Anuja Roy; Anita Burrell; Carol J Fairchild; Mahesh J Fuldeore; Daniel A Ollendorf; Peter K Wong Journal: Value Health Date: 2008 Jan-Feb Impact factor: 5.725
Authors: Prudence A Francis; Olivia Pagani; Gini F Fleming; Barbara A Walley; Marco Colleoni; István Láng; Henry L Gómez; Carlo Tondini; Eva Ciruelos; Harold J Burstein; Hervé R Bonnefoi; Meritxell Bellet; Silvana Martino; Charles E Geyer; Matthew P Goetz; Vered Stearns; Graziella Pinotti; Fabio Puglisi; Simon Spazzapan; Miguel A Climent; Lorenzo Pavesi; Thomas Ruhstaller; Nancy E Davidson; Robert Coleman; Marc Debled; Stefan Buchholz; James N Ingle; Eric P Winer; Rudolf Maibach; Manuela Rabaglio-Poretti; Barbara Ruepp; Angelo Di Leo; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Meredith M Regan Journal: N Engl J Med Date: 2018-06-04 Impact factor: 91.245
Authors: Lindsay J Collin; Deirdre P Cronin-Fenton; Thomas P Ahern; Michael Goodman; Lauren E McCullough; Lance A Waller; Anders Kjærsgaard; Per Damkier; Peer M Christiansen; Bent Ejlertsen; Maj-Britt Jensen; Henrik Toft Sørensen; Timothy L Lash Journal: Clin Cancer Res Date: 2020-12-17 Impact factor: 13.801
Authors: Christina Davies; Hongchao Pan; Jon Godwin; Richard Gray; Rodrigo Arriagada; Vinod Raina; Mirta Abraham; Victor Hugo Medeiros Alencar; Atef Badran; Xavier Bonfill; Joan Bradbury; Michael Clarke; Rory Collins; Susan R Davis; Antonella Delmestri; John F Forbes; Peiman Haddad; Ming-Feng Hou; Moshe Inbar; Hussein Khaled; Joanna Kielanowska; Wing-Hong Kwan; Beela S Mathew; Indraneel Mittra; Bettina Müller; Antonio Nicolucci; Octavio Peralta; Fany Pernas; Lubos Petruzelka; Tadeusz Pienkowski; Ramachandran Radhika; Balakrishnan Rajan; Maryna T Rubach; Sera Tort; Gerard Urrútia; Miriam Valentini; Yaochen Wang; Richard Peto Journal: Lancet Date: 2013-03-09 Impact factor: 79.321
Authors: Christoph Eisen; Zrinka Lulic; Juan Manuel Palacios-Moreno; Burkay Adalig; Michael Hennig; Vanessa Cortes; Florian Gilg; Karel Kostev Journal: Int J Clin Pharmacol Ther Date: 2020-01 Impact factor: 1.366